The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry

Introduction. The data assessing the impact of beta blocker (BB) medication on survival in patients after heart transplantation (HTx) are scarce and unequivocal; therefore, we investigated this population. Methods. We retrospectively analyzed the HTx Zabrze Registry of 380 consecutive patients who s...

Full description

Saved in:
Bibliographic Details
Main Authors: Grzegorz M. Kubiak, Radosław Kwieciński, Agnieszka Ciarka, Andrzej Tukiendorf, Piotr Przybyłowski, Tomasz Hrapkowicz, Michał O. Zembala
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/5190248
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850161731599335424
author Grzegorz M. Kubiak
Radosław Kwieciński
Agnieszka Ciarka
Andrzej Tukiendorf
Piotr Przybyłowski
Tomasz Hrapkowicz
Michał O. Zembala
author_facet Grzegorz M. Kubiak
Radosław Kwieciński
Agnieszka Ciarka
Andrzej Tukiendorf
Piotr Przybyłowski
Tomasz Hrapkowicz
Michał O. Zembala
author_sort Grzegorz M. Kubiak
collection DOAJ
description Introduction. The data assessing the impact of beta blocker (BB) medication on survival in patients after heart transplantation (HTx) are scarce and unequivocal; therefore, we investigated this population. Methods. We retrospectively analyzed the HTx Zabrze Registry of 380 consecutive patients who survived the 30-day postoperative period. Results. The percentage of patients from the entire cohort taking BBs was as follows: atenolol 24 (17%), bisoprolol 67 (49%), carvedilol 11 (8%), metoprolol 28 (20%), and nebivolol 8 (6%). The patients receiving BBs were older (56.94 ± 14.68 years vs. 52.70 ± 15.35 years, p=0.008) and experienced an onset of HTx earlier in years (11.65 ± 7.04 vs. 7.24 ± 5.78 p≤0.001). They also had higher hematocrit (0.40 ± 0.05 vs. 0.39 ± 0.05, p=0.022) and red blood cells (4.63 (106/μl) ± 0.71 vs. 4.45 (106/μl) ± 0.68, p=0.015). Survival according to BB medication did not differ among the groups (p=0.655) (log-rank test). Univariate Cox proportional hazard regression analysis revealed that the following parameters were associated with unfavorable diagnosis: serum concentration of albumin (g/l) HR: 0.87, 95% CI (0.81–0.94), p=0.0004; fibrinogen (mg/dl) HR: 1.006, 95% CI (1.002–1.008), p=0.0017; and C-reactive protein (mg/l) HR: 1.014, 95% CI (1.004–1.023), p=0.0044. Conclusions. The use of BBs in our cohort of patients after HTx was not associated with survival benefits.
format Article
id doaj-art-fa1169ef121b4315b19d2ea02c7624a0
institution OA Journals
issn 2090-8016
2090-0597
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-fa1169ef121b4315b19d2ea02c7624a02025-08-20T02:22:44ZengWileyCardiology Research and Practice2090-80162090-05972020-01-01202010.1155/2020/51902485190248The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx RegistryGrzegorz M. Kubiak0Radosław Kwieciński1Agnieszka Ciarka2Andrzej Tukiendorf3Piotr Przybyłowski4Tomasz Hrapkowicz5Michał O. Zembala6Department of Cardiac Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, PolandDepartment of Cardiac Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, PolandDepartment of Cardiovascular Diseases, Catholic University of Leuven, Leuven, BelgiumDepartment of Public Health, Wrocław Medical University, Wrocław, PolandDepartment of Cardiac Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, PolandDepartment of Cardiac Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, PolandDepartment of Cardiac Vascular and Endovascular Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, PolandIntroduction. The data assessing the impact of beta blocker (BB) medication on survival in patients after heart transplantation (HTx) are scarce and unequivocal; therefore, we investigated this population. Methods. We retrospectively analyzed the HTx Zabrze Registry of 380 consecutive patients who survived the 30-day postoperative period. Results. The percentage of patients from the entire cohort taking BBs was as follows: atenolol 24 (17%), bisoprolol 67 (49%), carvedilol 11 (8%), metoprolol 28 (20%), and nebivolol 8 (6%). The patients receiving BBs were older (56.94 ± 14.68 years vs. 52.70 ± 15.35 years, p=0.008) and experienced an onset of HTx earlier in years (11.65 ± 7.04 vs. 7.24 ± 5.78 p≤0.001). They also had higher hematocrit (0.40 ± 0.05 vs. 0.39 ± 0.05, p=0.022) and red blood cells (4.63 (106/μl) ± 0.71 vs. 4.45 (106/μl) ± 0.68, p=0.015). Survival according to BB medication did not differ among the groups (p=0.655) (log-rank test). Univariate Cox proportional hazard regression analysis revealed that the following parameters were associated with unfavorable diagnosis: serum concentration of albumin (g/l) HR: 0.87, 95% CI (0.81–0.94), p=0.0004; fibrinogen (mg/dl) HR: 1.006, 95% CI (1.002–1.008), p=0.0017; and C-reactive protein (mg/l) HR: 1.014, 95% CI (1.004–1.023), p=0.0044. Conclusions. The use of BBs in our cohort of patients after HTx was not associated with survival benefits.http://dx.doi.org/10.1155/2020/5190248
spellingShingle Grzegorz M. Kubiak
Radosław Kwieciński
Agnieszka Ciarka
Andrzej Tukiendorf
Piotr Przybyłowski
Tomasz Hrapkowicz
Michał O. Zembala
The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
Cardiology Research and Practice
title The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
title_full The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
title_fullStr The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
title_full_unstemmed The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
title_short The Impact of Beta Blockers on Survival in Heart Transplant Recipients: Insights from the Zabrze HTx Registry
title_sort impact of beta blockers on survival in heart transplant recipients insights from the zabrze htx registry
url http://dx.doi.org/10.1155/2020/5190248
work_keys_str_mv AT grzegorzmkubiak theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT radosławkwiecinski theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT agnieszkaciarka theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT andrzejtukiendorf theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT piotrprzybyłowski theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT tomaszhrapkowicz theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT michałozembala theimpactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT grzegorzmkubiak impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT radosławkwiecinski impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT agnieszkaciarka impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT andrzejtukiendorf impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT piotrprzybyłowski impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT tomaszhrapkowicz impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry
AT michałozembala impactofbetablockersonsurvivalinhearttransplantrecipientsinsightsfromthezabrzehtxregistry